The American journal of otology · 1998
Long-term results with the titanium bone-anchored hearing aid: the U.S. experience.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wazen J J, Caruso M, Tjellstrom A
Аннотация
OBJECTIVE: The purpose of this study is to evaluate the long-term safety and efficacy of the titanium bone-anchored hearing aid (BAHA).
STUDY DESIGN: A retrospective review of 24 patients implanted with the BAHA between 1984 and 1987 in a multiinstitutional study designed to evaluate the device in the United States was performed, including detailed clinical and audiologic evaluations of the 10 patients implanted at the Columbia-Presbyterian Medical Center in New York. The data were collected from patients' charts, questionnaires, and the Nobel Biocare patient contact and repair records.
PATIENTS: Candidates for the BAHA are unable to use a conventional air conduction hearing aid because of congenital aural atresia, draining mastoid cavities, or recurrent otitis externa. The audiologic indications are a conductive or a mixed hearing loss with a bone conduction average of 45 db or better and a speech discrimination score of 60% or better.
INTERVENTION: A BAHA was implanted in a two-stage procedure under local anesthesia on an outpatient basis.
MAIN OUTCOME MEASURES: Patients' satisfaction with the device, hearing improvement, and complication rates were reviewed.
RESULTS: The majority of the patients analyzed (78%) are still using the device an average of 15.6 hours/day 10 to 13 years after implantation. The overall satisfaction score was 4.5 (1, worst; 5, best). In sound field testing, the mean speech reception threshold improved from 52 db to 27 db (p < 0.05). There were no major complications.
CONCLUSION: The BAHA is a safe and effective bone conduction hearing aid with wide applications for patients with bone conduction hearing levels of 45 db and discrimination scores of 60% or better.
STUDY DESIGN: A retrospective review of 24 patients implanted with the BAHA between 1984 and 1987 in a multiinstitutional study designed to evaluate the device in the United States was performed, including detailed clinical and audiologic evaluations of the 10 patients implanted at the Columbia-Presbyterian Medical Center in New York. The data were collected from patients' charts, questionnaires, and the Nobel Biocare patient contact and repair records.
PATIENTS: Candidates for the BAHA are unable to use a conventional air conduction hearing aid because of congenital aural atresia, draining mastoid cavities, or recurrent otitis externa. The audiologic indications are a conductive or a mixed hearing loss with a bone conduction average of 45 db or better and a speech discrimination score of 60% or better.
INTERVENTION: A BAHA was implanted in a two-stage procedure under local anesthesia on an outpatient basis.
MAIN OUTCOME MEASURES: Patients' satisfaction with the device, hearing improvement, and complication rates were reviewed.
RESULTS: The majority of the patients analyzed (78%) are still using the device an average of 15.6 hours/day 10 to 13 years after implantation. The overall satisfaction score was 4.5 (1, worst; 5, best). In sound field testing, the mean speech reception threshold improved from 52 db to 27 db (p < 0.05). There were no major complications.
CONCLUSION: The BAHA is a safe and effective bone conduction hearing aid with wide applications for patients with bone conduction hearing levels of 45 db and discrimination scores of 60% or better.